A Study of AQUAVAN® Injection in the Presence of Pre-Medication in Patients Undergoing Elective Colonoscopy

This study has been completed.

First Received: September 13, 2005 Last Updated: November 6, 2008 History of Changes

Sponsors and Collaborators:	Eisai Medical Research Inc. Omnicare Clinical Research Bio Analytical Research Corporation MDS Pharma Services The Coghlan Group (Plasma Sample Supplies) HHI Clinical Research (Biostatistics)
Information provided by:	Eisai Medical Research Inc.
ClinicalTrials.gov Identifier:	NCT00209534

Purpose

This study was designed to assess the safety and efficacy of AQUAVAN® Injection in providing adequate sedation in patients undergoing colonoscopy. Prior to the procedure, patients received fentanyl citrate for pain management followed five minutes later by AQUAVAN® Injection for sedation. Throughout the procedure, study personnel assessed the patient's vital signs and depth of sedation. After the procedure, the patient, physician, and an evaluator were asked to complete satisfaction surveys.

Condition	Intervention	Phase
Colonoscopy Colon Polyps	Drug: fospropofol disodium	Phase II

MedlinePlus related topics: Colonic Polyps Colonoscopy

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Dose Comparison, Factorial Assignment, Safety/Efficacy Study
Official Title:	A Phase 2, Two Part Study of AQUAVAN® Injection in the Presence of Pre-Medication in Patients Undergoing Elective Colonoscopy

Further study details as provided by Eisai Medical Research Inc.:

Primary Outcome Measures:

The primary efficacy objective was to determine the desired sedative dose/dose range and dosing paradigm of AQUAVAN, defined as one that consistently provided mild-to-moderate sedation (Modified OAA/S >=2 and <=4) in a majority of patients.

Secondary Outcome Measures:

Efficacy variables included: time to sedation, time to Fully Alert, time to Fully Recovered, time to Ready for Discharge, Modified OAA/S scores over time, number of doses and amount of AQUAVAN, and Patient and Physician Satisfaction Surveys.

Estimated Enrollment:	200
Study Start Date:	January 2003
Study Completion Date:	February 2004

Detailed Description:

Randomized, open label, multi-center, adaptive dose ranging study, in which several dose levels of AQUAVAN® Injection and fentanyl citrate injection will be investigated to produce a desired sedation level in patients undergoing elective colonoscopy. A desired sedative dose/dose range and dosing paradigm will be identified based on pre-set criteria using the Modified Observer's Assessment of Alertness/Sedation (OAA/S). The desired sedative dose/dose range and dosing paradigm of AQUAVAN® Injection is defined as one that consistently provides mild to moderate sedation (Modified OAA/S between 2 and 4 inclusive) in a majority of patients who are pre-medicated with fentanyl citrate injection.

Eligibility

Ages Eligible for Study:	18 Years to 85 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients provided written informed consent after receiving a full explanation of the extent and nature of the study.
Patients were >=18 years of age to ≤60 years (a subset of up to 50 patients >60 years and <85 years of age was allowed).
Patients, if female, were surgically sterile, postmenopausal or non-pregnant using an acceptable method of birth control for at least 1 month prior to dosing, with a negative urine pregnancy test result at screening and predose.
Body mass index (BMI) between 20 and 28.
Body weight between 50 kg and 100 kg.
Patients had an ASA Physical Classification System status of I or II;
Patients required an elective colonoscopy procedure that was anticipated to be performed in <60 minutes (i.e., procedure was predicted to be uncomplicated); desired sedation for the colonoscopy procedure; and were determined by the Investigator to be physically capable of maintaining an adequate airway during mild-to-moderate sedation.

Exclusion Criteria:

Patients ingested benzodiazepines or barbiturates within 14 days of study start, with the exception of phenobarbital, which required a 21-day washout.
Patients ingested opioids within 72 hours of study start.
Patients had current symptoms of upper respiratory infection.
Patients had a history of allergic reaction or hypersensitivity to any anesthetic agent, narcotic, or benzodiazepine.
Patients had current signs of significant hiatal hernia, esophageal reflux, or heartburn which, in the opinion of the Investigator, could interfere with maintenance of an adequate airway.
Patients had a history of alcohol or drug abuse within the past 12 months;
Patients ingested alcohol or caffeine within 12 hours prior to admission into the study.
Patients participated in an investigational drug study within 1 month prior to study start.
Patients were unwilling to adhere to preprocedural and postprocedural instructions.
Patients donated >300 mL of blood within 1 month prior to study start; or
Patients were exposed to AQUAVAN in a previous clinical trial.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00209534

Sponsors and Collaborators

Eisai Medical Research Inc.

Omnicare Clinical Research

Bio Analytical Research Corporation

MDS Pharma Services

The Coghlan Group (Plasma Sample Supplies)

HHI Clinical Research (Biostatistics)

Investigators

Study Director:

James Jones, MD,PharmD

Eisai Medical Research Inc.

More Information

No publications provided

Study ID Numbers:	3000-0207
Study First Received:	September 13, 2005
Last Updated:	November 6, 2008
ClinicalTrials.gov Identifier:	NCT00209534 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Pathological Conditions, Anatomical
Colonic Polyps
Polyps

Additional relevant MeSH terms:

Pathological Conditions, Anatomical
Intestinal Polyps
Colonic Polyps
Polyps

ClinicalTrials.gov processed this record on May 07, 2009